Publication number: 20230405139
Abstract: The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.
Type:
Application
Filed:
June 13, 2023
Publication date:
December 21, 2023
Inventors:
Yun-Hee Park, Ho Young Song, Hyun Min Ryu, Sung Min Kim, Ju Yuel Baek, Ji Hye Oh, Nara Han, Hyoung Rae Kim, Kyung Eun Park, Hyeun Joung Lee, Ju Young Lee, Dae Hyuck Kang, Young-Jae Yang, Ji-na You, Yong Zu Kim, Chang Sun Lee, Jeiwook Chae, Jinwon Jung, Juhee Kim, Bora Lee, Daehae Song, Byungje Sung, Donghoon Yeom, Jaehyun Eom, Youngeun Hong, Jinhyung Ahn, Yangsoon Lee, Kyungjin Park, Jiseon Yoo, Minji Park
Patent number: 11707533
Abstract: The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.
Type:
Grant
Filed:
July 27, 2020
Date of Patent:
July 25, 2023
Assignees:
LegoChem Biosciences, Inc., ABL Bio, Inc.
Inventors:
Yun-Hee Park, Ho Young Song, Hyun Min Ryu, Sung Min Kim, Ju Yuel Baek, Ji Hye Oh, Nara Han, Hyoung Rae Kim, Kyung Eun Park, Hyeun Joung Lee, Ju Young Lee, Dae Hyuck Kang, Young-Jae Yang, Ji-Na You, Yong Zu Kim, Chang Sun Lee, Jeiwook Chae, Jinwon Jung, Juhee Kim, Bora Lee, Daehae Song, Byungje Sung, Donghoon Yeom, Jaehyun Eom, Youngeun Hong, Jinhyung Ahn, Yangsoon Lee, Kyungjin Park, Jiseon Yoo, Minji Park
Publication number: 20210069342
Abstract: The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.
Type:
Application
Filed:
July 27, 2020
Publication date:
March 11, 2021
Inventors:
Yun Hee Park, Ho Young Song, Hyun Min Ryu, Sung Min Kim, Ju Yuel Baek, Ji Hye Oh, Nara Han, Hyoung Rae Kim, Kyung Eun Park, Hyeun Joung Lee, Ju Young Lee, Dae Hyuck Kang, Young-Jae Yang, Ji-Na You, Yong Zu Kim, Chang Sun Lee, Jeiwook Chae, Jinwon Jung, Juhee Kim, Bora Lee, Daehae Song, Byungje Sung, Donghoon Yeom, Jaehyun Eom, Youngeun Hong, Jinhyung Ahn, Yangsoon Lee, Kyungjin Park, Jiseon Yoo, Minji Park
Patent number: 9630977
Abstract: The present invention relates to novel cephalosporin derivatives represented by X, Y, L, R1, and R2 are as same as defined in the description of the invention. The present invention also relates to pharmaceutical antibiotic compositions comprising a novel celphalosporin derivative represented by Chemical Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient. According to the present invention, novel cephalosporin derivatives, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient for the broad spectrum of antibiotic resistant, low toxicity, particularly in Gram-negative bacteria, which can be useful with strong antimicrobial activity.
Type:
Grant
Filed:
November 30, 2012
Date of Patent:
April 25, 2017
Assignee:
Legochem Biosciences, Inc.
Inventors:
Young Lag Cho, Joung Yul Yun, Sang Eun Chae, Chul Soon Park, Hyang Sook Lee, Kyu Man Oh, Hye Jin Heo, Dae Hyuck Kang, Young Jae Yang, Hyun Jin Kwon, Tae Kyo Park, Sung Ho Woo, Yong Zu Kim
Publication number: 20120264727
Abstract: The present invention relates to novel cephalosporin derivatives represented by Chemical Formula 1. Wherein, X, Y, L, R1, and R2 are as same as defined in the description of the invention. The present invention also relates to pharmaceutical antibiotic compositions comprising a novel celphalosporin derivative represented by Chemical Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient. According to the present invention, novel cephalosporin derivatives, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient for the broad spectrum of antibiotic resistant, low toxicity, particularly in Gram-negative bacteria, which can be useful with strong antimicrobial activity.
Type:
Application
Filed:
May 8, 2012
Publication date:
October 18, 2012
Applicant:
Legochem Biosciences, Inc.
Inventors:
Young Lag CHO, Hye Jin HEO, Kyu Man OH, Hyang Sook LEE, Chul Soon PARK, Sang Eun CHAE, Joung Yul YUN, Hyun Jin KWON, Young Jae YANG, Dae Hyuck KANG, Yong Zu KIM, Sung Ho WOO, Tae Kyo PARK